Description
Added on the 25/04/2021 14:00:00 - Copyright : EFE Inglés
Tehran, Mar 15 (EFE) .- (Camera: Marina Villén) The Iranian vaccine candidate against Covid-19 COVIRAN Barekat entered the second phase of clinical trials on Monday, being the first to advance to this point in the Persian country after verifying its efficacy and safety.FOOTAGE OF THE VACCINE TRIALS IN TEHRAN
Tehran (Iran), Feb 28 (EFE).- (Camera: Marina Villén) Iran began on Sunday clinical trials of the locally made Razi Cov Pars coronavirus vaccine, the second to be tested on the country's population.FOOTAGE OF THE START OF CLINICAL TRIALS. SOUNDBITES OF AMIR HOSEIN AMANPUR, 23-YEAR-OLD VOLUNTEER.
Russia is in an uproar after a health official said people shouldn't drink alcohol two weeks before and six weeks after getting the COVID-19 vaccine. According to Business Insider, there's no evidence that alcohol consumption is linked to Sputnik V's vaccine efficacy--or any other vaccine's efficacy. However, booze has been found to weaken the immune system. There is a waiting period of 21 days between the first and second Sputnik V shots. Having a strong immune system is especially important during a pandemic, so it may be wise to cut back on alcohol for that reason. The Russians have yet to release their complete, peer-reviewed data from phase 1 and 2 trials of Sputnik V, creating an air of secrecy around the vaccine.
Srinagar, India, Dec 7 (EFE).- "Covaxin", the first potential vaccine developed by an Indian laboratory against COVID-19, entered its third phase of clinical trials Monday with the application of doses in the city of Bhopal.India, which yesterday exceeded 140,000 deaths from COVID-19, is the second country in the world most affected by the pandemic, only behind the United States, with 9.6 million confirmed cases, 32,981 of them registered in the last 24 hours .India, known as the third world pharmacy for its high production of low-cost generics, is also positioned as one of the main candidates for the global manufacture of high doses of the vaccine once a definitive one is obtained.(Camera: SANJEEV GUPTA)SHOT LIST: INDIGENOUS COVAXIN PHASE 3 CLINICAL TRIALS IN BHOPAL, INDIA.
A new study reveals a COVID-19 vaccine under development in England safely promotes an immune response against the virus. According to UPI, the vaccine is in Phase 2 of clinical trials with Astra Zeneca, and is particularly effective in elderly recipients who are over age 70. Researchers say the finding of the 'robust' responses in older people in their study is both significant and encouraging. The populations at greatest risk of serious COVID-19 disease include people with existing health conditions and older adults. The so-called "Oxford vaccine," formally known as ChAdOx1 nCoV-19, is one of more than 120 being evaluated in response to the COVID-19 pandemic. To date, 48 of these vaccines have gotten into clinical trials to assess their safety and efficacy.
|
Support : Technical 
- Content 
- Editors 
